NOVALIQ RAISES NEW CAPITAL TO ACCELERATE THE COMMERCIALIZATION OF ITS LEAD PRODUCTS FOR DRY EYE DISEASE
Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces it has raised USD 53 million to further support its late-stage products and earlier pipeline programs.